Larazotide
Clinical TrialsLarazotide acetate
A tight junction peptide regulator researched for leaky gut, celiac disease, and intestinal permeability. One of the most promising gut barrier research peptides.
Dose
0.5 mg - 4 mg
Route
Oral
Cycle
Typically 12-24 weeks in research settings, some studies up to 1 year
Storage
Store at 2-8°C (refrigerated) away from light.
What is Larazotide?
Larazotide acetate is a synthetic peptide researched for its ability to regulate intestinal tight junctions and reduce intestinal permeability. It is commonly discussed in the context of 'leaky gut' and celiac disease, where compromised gut barrier function is a significant factor. Mechanistically, larazotide is believed to interfere with the zonulin pathway, a key regulator of intestinal permeability. By potentially normalizing tight junction function, it aims to reduce the passage of antigens and toxins from the gut lumen into the systemic circulation. Research protocols typically involve oral administration due to its localized action within the gastrointestinal tract.
Key Benefits
- Gut barrier protection
- Tight junction regulation
- Intestinal permeability reduction
- Celiac disease research
- Leaky gut research
Mechanism of Action
- Regulates tight junction proteins
- Reduces intestinal permeability
- Antagonizes zonulin pathway
- Protects gut epithelial barrier
Best For
- Gut permeability research
- Celiac disease research
- Digestive health
Body Systems
🐾 Griffin Says...
Molecular Information
Molecular weight
1298.4 g/mol
Length
12 amino acids
Type
Peptide
Amino acid sequence
H-Gly-Gly-Val-Leu-Ser-Phe-Ala-Gly-Leu-Asn-Ala-OH (GGVLSFAGLNA)
Larazotide is a modified 8-mer peptide with additional residues, often referenced as AT-1001. The sequence can also be presented with the N-terminal Glycine and C-terminal Alanine residues extended to a 12-mer for stability and activity.
Research Indications
Intestinal Permeability Reduction
Widely researched for its ability to reduce 'leaky gut' by modulating tight junction proteins and decreasing paracellular transport of molecules.
Tight Junction Regulation
Acts on the zonulin pathway, which is implicated in the opening of tight junctions, thereby helping to restore gut barrier integrity.
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Celiac Disease - Symptom Reduction (Adults) | 0.5 mg - 4 mg | 3 times daily | Oral |
| Celiac Disease - Mucosal Healing (Adults) | 0.5 mg - 4 mg | 3 times daily | Oral |
| Intestinal Permeability (General) | 0.5 mg - 4 mg | 3 times daily | Oral |
| Exploratory for Non-Celiac Gluten Sensitivity | 1 mg - 4 mg | 3 times daily | Oral |
| Adjunct to Gluten-Free Diet in Pediatric Celiac Patients | 0.5 mg - 2 mg (dose adjusted for weight/age) | 3 times daily | Oral |
Administer orally before meals, typically 30 minutes prior, to optimize contact with the intestinal lining before food intake.
Peptide Interactions
- Monitor Combination
Gluten (in celiac disease research)
Larazotide is often studied in conjunction with controlled gluten exposure in research to assess its protective effects against gluten-induced damage in celiac disease patients. It is not intended as a replacement for a gluten-free diet.
- Compatible
Immunosuppressants
No direct contraindications are commonly discussed; however, the impact of improved gut barrier on systemic immune responses is an area of ongoing research, especially in autoimmune conditions.
- Synergistic
Probiotics/Prebiotics
The combination is often considered synergistic in gut health research, as probiotics and prebiotics can support a healthy gut microbiome, while larazotide addresses barrier function.
- Monitor Combination
NSAIDs (Nonsteroidal Anti-inflammatory Drugs)
NSAIDs can exacerbate intestinal permeability. Research may explore if larazotide can mitigate NSAID-induced gut barrier damage, but specific interaction data are limited.
- Compatible
Other Gut Motility Modulators
No specific adverse interactions are commonly noted. Its action is distinct from agents affecting gut motility directly.
How to Reconstitute
What to Expect
- Weeks 1-4: Initial subjective improvements in digestive comfort or reduction in symptom severity may begin to be reported in some research subjects.
- Weeks 4-8: More consistent observations of improved gut barrier function, such as reduced markers of intestinal permeability, may start to be evident in research models.
- Weeks 8-12: Further stabilization of gut barrier integrity and potential reduction in inflammatory markers associated with increased permeability.
- Weeks 12-24: Sustained improvements in gut health parameters are commonly discussed, with ongoing studies sometimes extending to 6-12 months for long-term efficacy and safety.
- Long-term (beyond 24 weeks): Continued monitoring for sustained benefits in chronic conditions, particularly in studies investigating its role in managing conditions like celiac disease.
- Note: Individual responses in research subjects can vary widely based on baseline health, severity of condition, and other confounding factors.
Side Effects & Safety
| Effect | Frequency | Severity |
|---|---|---|
| Headache | Uncommon | Mild |
| Nausea | Uncommon | Mild |
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open CalculatorPeptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.